RT Journal Article
T1 Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase
A1 Seijas-Amigo, José
A1 Salgado Barreira, Ángel
A1 Castelo Domínguez, Rosana
A1 Pérez-Álvarez, María Teresa
A1 Ponce-Piñón, Belén
A1 Fernández-Silva, Marlén
A1 Rodríguez Barreiro, Marta
A1 Pereira-Pía, Mercedes
A1 Iglesias-Moreno, José Manuel
A1 Gago-García, Mar
A1 Montáns-García, Raquel
A1 Fernández-Pérez, Agustina
A1 Fraga Gayoso, Dolores
A1 Fernández-Montenegro, Montse
A1 Riveiro-Barciela, Beatriz
A1 Rilla-Villar, Natalia
A1 Cordero, Alberto
A1 Rodríguez Mañero, Moisés
A1 González Juanatey, José Ramón
K1 Obesity
K1 Weight change
K1 Glucagon-like peptide 1
K1 Safety
K1 Adherence
K1 Glycemic control
K1 Type 2 diabetes
AB IntroductionObesity increases the risk of type 2 diabetes mellitus and cardiovascular disease (CVD). Weight loss (≥5 %) reduces the risk of CVD. Glucagon-like peptide-1 receptor agonists (GLP1 RA) have shown clinically weight loss. Objectives: 1) To assess differences in the efficacy of weight loss and HbA1c; 2) to evaluate the safety and adherence during the titration phase.MethodsIt is a multicenter, prospective, and observational study on GLP1 RA naïve patients. The primary end point was the weight loss (≥5 %). Changes in weight, BMI and HbA1c were also calculated as co-primary endpoints. Secondary endpoints were safety, adherence, and tolerance.ResultsAmong 94 subjects, 42.4 % received dulaglutide, 29,3 % subcutaneous semaglutide, 22,8 % oral semaglutide. 45 % female and the mean age was 62. Baseline characteristics were body weight 99.3 kg, BMI 36.7 kg/m2 and Hba1c 8.2 %. Oral semaglutide achieved the highest reduction: 61.1 % of patients achieving ≥ 5 %, subcutaneous semaglutide 45.8 % and dulaglutide 40.6 %. GLP1 RA significantly reduced body weight (−4.95 kg, p < 0.001) and BMI (−1.86 kg/m2, p < 0.001), without significant differences between groups. Gastrointestinal disorders were the most frequently reported events (74.5 %). 62 % of patients on dulaglutide, 25 % on oral semaglutide and 22 % on subcutaneous semaglutide.ConclusionsOral semaglutide achieved the highest proportion of patients that lost ≥ 5 %. GLP1 RA significantly reduced BMI and HbA1c. Most of the reported adverse events were gastrointestinal disorders and they were reported in a major frequency in the dulaglutide group. Oral semaglutide would be a reasonable switch in case of future shortages
PB Elsevier
SN 1751-9918
YR 2023
FD 2023-05-23
LK http://hdl.handle.net/10347/31267
UL http://hdl.handle.net/10347/31267
LA eng
NO Primary Care Diabetes 17 4 (2023) 366-372
DS Minerva
RD 24 abr 2026